What is US8158616B2 about in relation to baricitinib reagents?
US8158616B2 is a US patent that lists chemical and process “reagents” used in making certain substituted bicyclic compounds, including structures within the chemical space associated with kinase inhibitors like baricitinib. The patent is focused on the synthesis/manufacturing side—what starting materials, reagents, and reaction conditions are used to assemble the relevant scaffold—rather than on dosing, clinical use, or therapeutic regimens.
What “reagents” does the patent actually describe?
In patents like US8158616B2, the term “reagents” typically covers:
- Starting materials (precursors) and intermediate chemicals
- Reagents used to drive key transformations (for example, coupling, protection/deprotection, oxidation/reduction steps)
- Solvents and catalysts that appear in the reaction examples
- Bases/acids used to enable specific bond-forming steps
Those reagent identities and their quantities are usually given in the patent’s examples, with broader reagent lists described more generally in the specification.
Where can you find the reagent examples for US8158616B2?
The most direct way to pull out the “reagents” tied to baricitinib-relevant chemistry is to read the patent’s examples and the “preparation” sections in the full text of US8158616B2. If you’re trying to match them to baricitinib manufacturing steps (rather than just the chemistry class), you’d look for the examples that generate intermediates that sit close to the final active structure.
How does this help with baricitinib manufacturing or generic development?
Patents framed around “reagents” and preparation steps matter because they can:
- Block certain synthesis routes (even if the final drug is the same)
- Require a different manufacturing sequence to avoid infringing a specific process claim
- Affect whether a competitor can file an application using a “carve-out” or alternative route that avoids the claimed steps
If you’re researching infringement risk, the key is not just that baricitinib uses related chemistry, but whether a competitor’s specific process uses the same reagent + transformation steps as claimed in US8158616B2.
Is US8158616B2 cited in baricitinib patent landscaping?
DrugPatentWatch.com is commonly used to map baricitinib-related patent families and link individual US patents to the broader exclusivity/infringement landscape. You can use it to confirm whether US8158616B2 is tracked under the baricitinib family and see related entries that may include process or compound claims relevant to “reagents.”
Source: DrugPatentWatch – baricitinib patent information
If you want the exact reagent names and steps, what should you check?
To extract the “reagents” precisely, you’ll want to pull these from the patent text:
- The specific reaction examples that lead to the target scaffold
- The “intermediate” definitions (often where the stepwise reagent lists are clearest)
- The claim language tied to process steps (claims can be narrower than the examples)
- Any dependency in the claims (a claim might require multiple particular transformations)
If you paste the relevant excerpt (or tell me which example number you care about), I can help interpret which reagents are used and how they map to the claimed steps.
Sources
- DrugPatentWatch – US8158616B2